Polymorphisms of β1-Adrenoreceptor Gene and Cardiovascular Complications in Patients with Thyrotoxicosis

Table 6

(a) Clinical and laboratory data of patients with thyrotoxicosis depending on genotype (Ser49Gly) before treatment. (b) Clinical and laboratory data of patients with thyrotoxicosis depending on genotype (Ser49Gly) after treatment.

(a)

	AA, 𝑛=100	AG, 𝑛=56	GG, 𝑛=9
Sex, male/female	F: 88 (62%); M: 12 (52.2%)	F: 46 (32.4%); M: 10 (43.5%)	F: 8 (5.6%); M: 1 (4.3%)
Age, years	42.1 ± 8.7	42.6 ± 10.3	45.7 ± 5.0
Thyrotoxicosis duration, month	93; 10; (6; 20)	54; 12; (6; 20)	9; 10; (8; 24)
HR, beats/min	95 ± 20	97 ± 17	92 ± 12
BP, systolic/diastolic, mmHg	129 ± 16/75 ± 9	130 ± 15/77 ± 10	130 ± 20/75 ± 9
FT3, pmol/L	39; 11.1; (9.0; 22.1)	20; 12.7; (9.7; 21.6)	3; 10.0; (9.0; 29.5)
FT4, pmol/L	47; 46.0; (30.5; 61.0)	28; 36.6; (26.0; 54.4)	4; 42.0; (23.8; 50.3)
T3, total, nmol/L	52; 5.2; (4.0; 7.9)	31; 4.1; (3.3; 6.8)	7; 5.2; (4.3; 9.0)
T4, total, nmol/L	54; 215; (185; 284)	29; 202; (164; 249)	5; 134; (116; 149)*

^∗𝑃=0.04 for GG versus allele A.

(b)

	AA, 𝑛=100	AG, 𝑛=56	GG, 𝑛=9
HR, beats/min	78 ± 14	77 ± 8	72 ± 12
BP, systolic/diastolic, mmHg	119 ± 14/70 ± 8	120 ± 13/71 ± 8	117 ± 16/73 ± 10
FT3, pmol/L	13; 6.0; (3.4; 7.9)	11; 5.4; (3.7; 7.7)	2; 2.3; (2.0; 2.6)
FT4, pmol/L	56; 15.0; (9.7; 25.0)	31; 11.4; (9.2; 17.0)	5; 19.4; (19.0; 19.4)
T3, total, pmol/L	24; 2.0; (1.6; 2.7)	11; 2.2; (1.4; 3.8)	1; 6.2;
T4, total, pmol/L	44; 107; (83; 137)	30; 104; (74; 116)	4; 119; (110; 128)*

^∗𝑃=0.01 for GG versus allele A.